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During the heterologous phase of experimental
anti-glomerular basement membrane (anti-GBM) nephritis,
leukocyte influx peaks within hours, whereas albuminuria
occurs within 1 day. In the subsequent autologous phase,
endogenous anti-GBM IgG develops and albuminuria
persists. Heparan sulfate (HS) proteoglycans like syndecan-1
play multiple roles during inflammation and we evaluate its
role in experimental anti-GBM disease using syndecan-1
knockout (sdc-1/) mice. During the heterologous phase,
glomerular leukocyte/macrophage influx was significantly
higher in the sdc-1/ mice and this was associated with
higher glomerular endothelial expression of specific HS
domains. In the autologous phase, glomerular influx of
CD4þ /CD8þ T cells was higher in the sdc-1/ mice and
these mice had persistently higher albuminuria and serum
creatinine levels than wild-type mice. This resulted in a more
sever glomerular injury and increased expression of
extracellular matrix proteins. The sdc-1/ mice developed
higher plasma levels and glomerular deposits of total mouse
Ig and IgG1 anti-rabbit IgG, whereas the levels of mouse
IgG2a anti-rabbit IgG were lower. Furthermore, decreased
Th1 and higher Th2 renal cytokine/chemokine expression
were found in the sdc-1/ mice. Our studies show that
syndecan-1 deficiency exacerbates anti-GBM nephritis
shifting the Th1/Th2 balance towards a Th2 response.
Kidney International (2007) 72, 1204–1215; doi:10.1038/sj.ki.5002514;
published online 5 September 2007
KEYWORDS: chemokine receptor; chemokine; adhesion molecule; heparan
sulfate; glomerulonephritis
The syndecans belong to a family with four members of type
I transmembrane heparan sulfate (HS) proteoglycans, which
consist of an extracellular N-terminal domain with several
HS side chains, a single hydrophobic transmembrane
domain, and a short C-terminal cytoplasmic domain.1
Syndecans are expressed in a developmental and cell-type-
specific pattern and act as co-receptors for various ligands
like growth factors and matrix molecules.1–3 Syndecan-1
(sdc-1; CD138) is expressed on epithelial cells, endothelial
cells, and leukocytes4 and appears to play a role in
tumorigenesis.5 During inflammation, the expression of
sdc-1 on both endothelial cells and leukocytes can be
upregulated, which suggests that sdc-1 also plays a role in
the interaction of leukocytes with endothelium.6,7 Sdc-1-
deficient mice5,8 develop normally and are fertile, but show
an enhanced adhesion of leukocytes in the ocular vasculature
and in mesentery venules after tumor necrosis factor (TNF)-a
treatment compared to wild type (WT) mice.9 The role of
sdc-1 in renal physiology and pathology remains elusive, but
it has been reported that the sdc-1 ectodomain is present in
the circulation of patients with type I diabetes and early
diabetic nephropathy.10
HS binds and modulates the activity of many inflam-
matory molecules such as chemokines, selectins, integrins,
and adhesion molecules.11,12 The linear HS side chains
are composed of about 150 U of glucosamine-uronic acid
disaccharides that can be sulfated at the N-position, 2-,
3-, and/or 6-O-position, and epimerized at the C-5 position
by a large family of HS-modifying enzymes.13 The number of
possible combinations of modifications within one HS chain
can give rise to an enormous structural diversity, which is
important for the specific binding of a myriad of factors. The
importance of specific N- and 6-O-sulfated HS domains on
activated endothelium for the adhesion of polymorpho-
nuclear granulocytes (PMNs) has been documented.12
Structural analysis of HS in kidney, lung, and spleen from
both WT and sdc-1-deficient mice revealed no differences in
HS disaccharide composition.14
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The experimental model of passive anti-glomerular base-
ment membrane (GBM) nephritis is induced by the
intravenous injection of heterologous anti-GBM antibodies,
which bind immediately to the GBM with subsequent
complement activation. In the early, acute heterologous,
phase, that is within hours after anti-GBM IgG administra-
tion, glomerular PMN influx is peaking, whereas albumin-
uria is manifested within 1 day.15–17 At high doses of
heterologous anti-GBM serum, the albuminuria and glome-
rular lesions in the acute phase of anti-GBM nephritis are
strictly PMN-dependent and complement-independent,18
whereas at lower doses of anti-GBM antibodies, also
complement-dependent mechanisms may be operative.19 In
particular, the cationic neutral proteinases elastase and
cathepsin G, which are released by activated PMNs,
contribute to glomerular damage and albuminuria in the
acute heterologous phase of anti-GBM nephritis, as beige
mice that are deficient in these proteinases failed to develop
albuminuria after induction of anti-GBM nephritis.20 The
integrin Mac-1, expressed by PMNs, probably interacts with
deposited C3 complement,21 which subsequently may lead to
the release of elastase and cathepsin G by the PMNs.20,21
Subsequently, these cationic proteinases bind to the GBM,
probably to anionic HS,22–24 which leads to increased GBM
permeability and albuminuria.21 The autologous phase of
anti-GBM nephritis is initiated by the immune response of
the host to the injected heterologous anti-GBM antibodies,
that is about 1 week after administration of anti-GBM anti-
bodies,25 and is characterized by persistent severe albumi-
nuria. The development of antibodies to the heterologous
anti-GBM antibodies has been identified as a Th1 response.26
The deposition of mouse Ig anti-rabbit IgG along the GBM
may be important for the persistence of albuminuria during
the autologous phase of anti-GBM nephritis.27
It is well established that HS proteoglycans like sdc-1 play
a crucial role in the leukocyte–endothelium interaction
during inflammation in different vascular beds.28,29 However,
there is little knowledge about the role of HS(PG)s in
glomerulonephritis, therefore, we evaluated experimental
anti-GBM nephritis in both WT and sdc-1-deficient mice.
RESULTS
Induction of anti-GBM nephritis in WT and sdc-1-deficient
mice and identification of the heterologous and autologous
phase
The generated rabbit anti-mouse serum stained at higher
dilutions exclusively the GBM of both sdc-1-deficient and
WT mice (data not shown). Furthermore, the rabbit anti-
mouse GBM antibodies reacted in enzyme-linked immuno-
sorbent assay with purified agrin, HS, laminin, fibronectin,
and collagen type IV (Figure 1). Administration of rabbit
anti-GBM antibodies to WT and sdc-1-deficient mice
resulted in a binding of rabbit IgG along the GBM already
after 1 h (Figure 2a and b; Table 1), which remained
unaffected until day 8. Rabbit IgG binding was accompanied
with C3c deposition in both mice strains, which started with
a fine granular staining along the GBM after 1 h, which
became linear after 2 h (Figure 2c and d; Table 1). Some
segmental staining of Bowman’s capsule and tubular base-
ment membranes was observed, which was also noted in mice
that received control rabbit IgG and has been described
previously.15 In both WT and sdc-1-deficient mice, focal and
segmental deposits of fibrin could be observed after 4 h,
which increased until day 8 (Figure 2e and f; Table 1). The
autologous phase started after 4 days as revealed by the
presence of mouse Ig anti-rabbit IgG along the capillary wall
in both mice strains. However, in sdc-1-deficient mice about
two-fold more mouse Ig anti-rabbit IgG was present along
the capillary wall after 4 and 8 days (Figure 2g–i; Table 1).
Administration of control rabbit IgG to WT and sdc-1-
deficient mice did not lead to glomerular binding and
deposition of C3c, fibrin or mouse Ig at all evaluated time
points (data not shown). These data indicate that sdc-1
deficiency does not affect the binding/deposition of rabbit
anti-mouse GBM IgG, C3c, and fibrin during the hetero-
logous and autologous phase of anti-GBM nephritis.
However, sdc-1 deficiency leads to an enhanced glomerular
deposition of mouse Ig anti-rabbit IgG during the autologous
phase.
Experimental anti-GBM nephritis leads to a higher
glomerular expression of sdc-1 and -4
Immunohistochemical analysis of sdc-1 and sdc-4 expression
in the normal kidney revealed a low expression level in
glomeruli whereas the expression was significantly upregu-
lated after 2 and 18 h during anti-GBM nephritis, which
decreased after 4 and 8 days to normal levels (Figure 3a and b).
Furthermore, the sdc-1 and -4 mRNA expression in renal
cortex significantly increased after 2 h during anti-GBM
nephritis, which persisted after 8 days (Table 2). Both at the
protein and the mRNA level, the glomerular expression of
sdc-4 increased in sdc-1-deficient mice after 2 and 18 h,
which decreased to normal levels after 4 and 8 days (Figure
3b; Table 2). It appeared that the mRNA expression of sdc-4
in sdc-1-deficient mice was lower compared with sdc-4
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Figure 1 | Rabbit anti-mouse GBM antibodies react with purified
collagen IV, laminin, HS, agrin, and fibronectin. Results are
expressed as means7s.e.m. optical density values at 450 nm from
three experiments.
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expression in scd-1-deficient mice during anti-GBM nephri-
tis, whereas sdc-4 protein expression was similar in WT and
sdc-1-deficient mice. Sdc-2 and -3 were not expressed in
glomeruli of normal kidneys of WT and sdc-1-deficient mice
(not shown), whereas at the mRNA level, the expression was
not changed during anti-GBM nephritis (Table 2). It can be
concluded that both sdc-1 and -4 play a role during anti-
GBM nephritis and that the other syndecan members do not
compensate for the sdc-1 deficiency.
Sdc-1 deficiency leads to a higher glomerular leukocyte
influx and a higher expression of inflammatory HS domains
on glomerular endothelium in anti-GBM nephritis
Next, we evaluated the glomerular influx of PMNs, being
one of the key determinants of glomerular damage and
albuminuria in the early phase of anti-GBM nephritis,
and the glomerular influx of macrophages and CD4þ and
CD8þ T cells. Glomerular PMN and macrophage influx
could be observed 1 h after administration of rabbit anti-
GBM IgG (Figure 4a and b), which was maximal after 2 h
and quickly decreased after 4–18 h. However, after 2 h, the
glomerular PMN and macrophage influx was significantly
higher in sdc-1-deficient mice compared with WT mice.
Furthermore, the macrophage influx in the interstitium was
significantly increased after 4 and 8 days and significantly
higher in sdc-1-deficient mice compared with WT mice
(data not shown). The glomerular influx of CD4þ and
CD8þ T cells was observed after 18 h and increased after
4 and 8 days, whereas this influx was higher in sdc-1-deficient
mice (Figure 4c and d).
Recently, we have identified an increased expression of
inflammatory N- and 6-O-sulfated HS domains on cultured
glomerular endothelial cells after activation with TNF-a,
which were directly involved in the adhesion of granulo-
cytes.30 The anti-HS antibodies AO4B08, EW3D10, and
EW4G2 identified these glomerular endothelial HS domains,
respectively. Now, we evaluated the expression of these
inflammatory HS domains on glomerular endothelium by
double staining with these specific anti-HS antibodies and an
anti-CD31 antibody. It appeared that the glomerular endo-
thelial expression of the N- and 6-O-sulfated HS domains
was significantly increased after 2 h in both WT and sdc-1-
deficient mice compared with untreated mice or mice that
received control rabbit IgG (Figure 5a–d). Interestingly, the
glomerular endothelial expression of the inflammatory HS
domains was significantly higher in sdc-1-deficient mice
compared with WT mice (Figure 5b–d). Expression analysis
of the endothelial activation marker intercellular adhesion
molecule-1 and the HS ligand L-selectin on leukocytes
revealed a higher expression in sdc-1-deficient mice com-
pared with WT mice after 2 h (Table 2). Taken together,
sdc-1-deficient mice show a higher number of glomerular
PMNs, macrophages, and CD4þ and CD8þ T cells, and
a higher glomerular endothelial expression of inflammatory
N- and 6-O-sulfated HS domains.
Sdc-1 deficiency leads to higher albuminuria, a worse renal
function, and more extensive glomerular injury in anti-GBM
nephritis
A significant albuminuria was already observed after 18 h in
the heterologous phase in both WT and sdc-1-deficient mice
(Figure 6a), which was significantly higher in sdc-1-deficient
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Figure 2 | Characteristics of the heterologous and autologous
phase of anti-GBM nephritis in WT and sdc-1-deficient mice.
Immunofluorescence staining 2 h after anti-GBM administration
revealed binding of (a, b) rabbit anti-GBM IgG and (c, d) mouse
complement 3c (C3c) along the capillary wall, which was similar
between (a, c) WT and (b, d) sdc-1-deficient mice. (e, f) At day 8 after
induction of anti-GBM nephritis, the glomerular deposition of fibrin
was similar between (e) WT and (f) sdc-1-deficient mice, whereas the
deposition of mouse anti-rabbit Ig along the capillary wall was higher
in (h) sdc-1-deficient mice compared with (g) WT mice (original
magnification  400). (i) Glomerular deposition of mouse Ig
anti-rabbit IgG was higher in sdc-1-deficient mice compared with
WT mice at 4 and 8 days after administration of rabbit anti-GBM IgG.
The titers (means7s.e.m.) are shown from eight WT and eight
sdc-1-deficient mice. *Po0.05 and **Po0.001 versus anti-GBM
injected WT mice. WT, wild type; Sdc-1/, syndecan-1-deficient.
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mice. Albuminuria increased further in the autologous phase
after 4 and 8 days, whereas the significant difference between
WT and sdc-1-deficient mice persisted (Figure 6a). The
renal function, that is the plasma creatinine concentration,
was unaffected during the heterologous phase (Figure 6b),
whereas plasma creatinine levels increased during the
autologous phase (Figure 6b). After 8 days, sdc-1-deficient
mice had significantly higher plasma creatinine levels com-
pared with WT mice. Mice that received control rabbit IgG
did not develop albuminuria or renal function impairment
(Figure 6a and b).
Renal histology after 18 h was similar in WT and sdc-1-
deficient mice, that is a minority of glomeruli showed
segmental or global endothelial swelling with occlusion of the
capillary lumens due to periodic acid-Schiff (PAS)-positive
fibrinous material. At day 4, approximately 50% of the
glomeruli of the sdc-1-deficient mice showed globally
occluded and distended capillaries filled with PAS-positive
fibrinous material, which was sporadically observed in WT
mice. In addition, proteinacious tubular casts were more
frequently observed in sdc-1-deficient mice compared with
WT mice (Figure 7). At day 8, the differences between WT
and sdc-1-deficient mice were even more pronounced, that is
in sdc-1-deficient mice, the majority of glomeruli showed
globally distended capillaries with PAS-positive material,
occasionally cellular crescents, whereas tubular casts were
frequent. In contrast, WT mice showed only thickening of the
capillary wall, mostly open capillary lumens and no crescents,
whereas tubular casts were sporadically observed (Figure 7).
Next, we evaluated the expression of extracellular matrix
components. As our anti-GBM serum reacts with collagen IV,
laminin, agrin, HS, and fibronectin (Figure 1), we used
digoxigenin-labeled rabbit anti-GBM serum, as a probe to
stain renal sections of untreated mice (WT and sdc-1-
deficient mice) and mice with anti-GBM nephritis at 2 h and
8 days. These data revealed that there is no difference in
expression between untreated WT and sdc-1-deficient mice,
but an increased expression of extracellular matrix compo-
nents in sdc-1-deficient mice compared with WT mice at day
8 due to expansion of GBM matrix (Figure S1). At the mRNA
level, the expression of the glomerular extracellular matrix
proteins collagen XVIII, fibronectin, collagen IV a3 through
a5, and laminin a5, b2, g1 was two- to three-fold higher in
the sdc-1-deficient mice compared with WT mice at day 8
(Table 2). The expression of agrin and the non-GBM collagen
IV chains a1 and a2, however, was not different. Further-
more, we found that the expression of the matrix remodeling
enzymes matrix metalloproteinase-7 and matrix metallopro-
Table 1 | Presence of rabbit IgG, C3c, fibrin, and mouse Ig anti-rabbit IgG during anti-GBM nephritis in wild type and
syndecan-1-deficient mice
Phase during anti-GBM nephritis Time Rabbit IgGa C3ca Fibrina
Mouse Ig anti-rabbit IgG
WT Sdc-1/
Heterologous 1 h ++++ ++ -  
2 h ++++ +++ 7  
4 h ++++ +++ +  
18 h ++++ + ++  
Autologous 4 days ++++ + +++ + ++
8 days ++++ + ++++ ++ ++++
C3c, complement 3c; Sdc-1/, syndecan-1-deficient; WT, wild type.
aDeposition in WT and syndecan-1-deficient mice is identical.
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Figure 3 | Glomerular expression of sdc-1 and -4 in WT and
sdc-1-deficient mice during anti-GBM nephritis. Glomerular
(a) sdc-1 and (b) sdc-4 protein expression increasedB3-fold at 2 and
18 h after the induction of anti-GBM nephritis in WT mice. At days
4 and 8, glomerular expression of sdc-1 and -4 became
normal (indicated by the dotted line). (b) Glomerular expression of
sdc-4 was also increased in sdc-1-deficient mice at 2 and 18 h after
the induction of anti-GBM nephritis and became normal at days 4
and 8. ^Po0.05 versus untreated mice or mice injected with control
rabbit IgG. WT, wild type mice; Sdc-1/, syndecan-1-deficient mice.
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teinase-9 was significantly higher in sdc-1-deficient mice at
day 8 (Table 2). Quantitative mRNA expression analysis of
the growth factors fibroblast growth factor, transforming
growth factor-b and connective tissue growth factor, how-
ever, revealed no significant differences between WT and sdc-
1-deficient mice after 2 h or 8 days.
Sdc-1 deficiency leads to a shift from a Th1 to a Th2 response
in anti-GBM nephritis
Sdc-1-deficient mice showed significantly more mouse
Ig anti-rabbit IgG along the capillary wall compared with
WT mice (Figure 1i). Evaluation of plasma levels of total mouse
Ig anti-rabbit IgG revealed in sdc-1-deficient mice two-fold
higher levels than in WT mice at days 4 (Figure 8a) and 8
(Figure 8b) after administration of rabbit anti-GBM IgG.
However, there was no difference in total mouse Ig anti-
rabbit IgG response when mice received control rabbit IgG.
Irrespective of the presence of sdc-1, the response against
rabbit anti-GBM IgG was significantly higher than the
response against control rabbit IgG (data not shown). It
has been described that the autologous phase in experimental
anti-GBM is characterized by a Th1 response.26 We deter-
mined plasma levels and glomerular deposition of two Ig
isotypes, IgG2a that is related to a Th1 response and IgG1
that is related to a Th2 response. It appeared that in sdc-1-
deficient mice plasma levels (Figure 8a and b) and glomerular
deposits (Figure 8c and d) of mouse IgG1 anti-rabbit IgG
were significantly higher, whereas plasma levels and glome-
rular deposits of mouse IgG2a anti-rabbit IgG were signi-
ficantly lower compared with WT mice after 4 (Figure 8a and
c) and 8 days (Figure 8b and d). We further analyzed Th1/
Th2 (promoting) cytokines/chemokines. At the mRNA level,
Table 2 | Quantitative mRNA expression of syndecans, extracellular matrix components, metalloproteases, growth factors,
cytokines, and chemokines in the renal cortex of wild type and syndecan-1-deficient mice during anti-GBM nephritisa
2 h 8 days
WT Sdc-1/ WT Sdc-1/
Sdc-1 6.8172.57&& ND 2.1070.36&& ND
Sdc-2 0.8370.39 0.8470.13 0.9470.20 1.0270.16
Sdc-3 0.7270.24 1.0370.21 1.0670.33 1.1670.27
Sdc-4 6.7071.95** 3.5270.88 2.7470.36** 1.7770.51
ICAM-1 22.2072.49 32.1573.41& 11.2973.54 10.1472.44
L-selectin 4.4271.27 14.0872.21& 1.4170.21 3.3070.92&
Fibronectin 1.0470.87 2.0571.18 6.5671.34 25.6172.46&
Agrin 1.5170.67 2.1571.22 3.2371.08 4.8471.27
Collagen XVIII 2.3171.01 1.6771.21 3.8771.36 8.4772.18*
Laminin a5 1.7170.54 1.4670.98 3.1471.52 6.2371.11*
Laminin b2 1.2470.63 1.2670.41 2.1171.54 7.2472.50*
Laminin g1 1.0670.13 1.6270.23 1.7470.72 3.4271.09*
Collagen IV a1 1.6670.3 1.4970.29 5.9171.43 5.2871.24
Collagen IV a2 0.9870.06 1.5670.16 1.5971.18 1.3571.43
Collagen IV a3 0.6670.13 1.5770.79 2.4871.11 4.9671.55*
Collagen IV a4 0.6670.21 1.1070.55 2.0370.21 4.1671.27*
Collagen IV a5 0.9570.12 1.9570.91 1.0370.32 3.3371.33*
MMP-7 1.5770.69 1.2370.22 28.2875.27 90.1578.42&
MMP-9 2.4170.98 3.6970.91 5.7472.18 13.8674.32*
TGF-b1 1.9770.22 2.267096 4.4371.38 3.7470.92
FGF-1 1.2370.38 1.8370.49 1.6770.09 1.4770.32
CTGF 1.0770.32 0.9070.23 7.8271.88 10.1872.11
IL-1b 12.6070.25 46.9070.32& 0.7370.21 0.9570.19
TNF-a 1.1070.09&& 0.4370.11 1.0270.21^ 0.4470.17
IFN-g 1.4470.14 1.5670.31 3.0270.09&& 0.9870.11
MCP-1 67.01715.42 192.67742.45^ 3.6271.32 13.6974.23^
MIP-1a 140.45731.37^^ 41.18718.39 0.9970.19 0.7870.22
IL-2 1.0370.27 0.8370.13 1.6670.13&& 0.8570.02
IL-4 0.4370.10 0.5870.21 0.4970.07 1.1970.08&
IL-6 24477568 37117654* 1.1370.23 1.1070.17
IL-10 0.6970.12 0.6670.08 0.7070.16 4.7570.18&
IL-12a 0.7170.13^^ 0.2770.15 0.7670.04&& 0.3770.05
IL-12b 0.4670.12^^ 0.1170.08 1.0070.06&& 0.4070.09
Tnfrsf1a 1.0770.23 0.9670.16 4.0471.13^^ 1.8470.12
Tnfrsf1b 3.2270.84 2.1970.97 17.2475.43** 8.5673.27
CTGF, connective tissue growth factor; GBM, glomerular basement membrane; FGF, fibroblast growth factor; ICAM-1, intercellular adhesion molecule-1; IFN-g, interferon-g;
IL, interleukin; MCP-1, monocyte chemotactic protein-1; MIP-1a, macrophage inflammatory protein 1a; MMP, matrix metalloproteinase; ND, not detectable; Sdc-1/,
syndecan-1-deficient mice; TGF, transforming growth factor; TNF-a, tumor necrosis factor-a, Tnfrsf, TNF receptor; WT, wild type mice.
The mean expression7s.d. of four mice per group are depicted. There were no differences in expression between untreated WT and sdc-1-deficient mice. The significant
highest expression is given in bold. *Po0.05 versus anti-GBM injected WT mice; ^Po0.01 versus anti-GBM injected WT mice; &Po0.001 versus anti-GBM injected WT mice;
**Po0.05 versus anti-GBM injected sdc-1-deficient mice; ^^Po0.01 versus anti-GBM injected sdc-1-deficient mice; &&Po0.001 versus anti-GBM injected sdc-1-deficient mice.
aThe relative expression compared with untreated WT or sdc-1/ mice is shown.
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an increased expression of the Th2 promoting and B cell
stimulating proinflammatory cytokine interleukin (IL)-1b
was observed in the sdc-1-deficient mice in the heterologous
phase. Furthermore, Th2 (promoting) cytokines IL-4, IL-6,
IL-10, IL-13, and monocyte chemotactic protein-1 were
higher in the sdc-1-deficient mice compared with WT mice
in the heterologous and/or autologous phase. Moreover,
Th1 (promoting/maintaining) cytokines TNF-a, interferon-g,
IL-2, IL-12a, IL-12b, and macrophage inflammatory protein
(MIP)-1a were lower in the sdc-1-deficient mice compared
with the WT mice in the heterologous and/or autologous
phase. Furthermore, the expression of TNF receptor 1a and
TNF receptor 1b was lower in the sdc-1-deficient mice
(Table 2). Using cytokine/chemokine arrays, we could
confirm the mRNA analysis data for interferon-g, IL-4, IL-
10, and monocyte chemotactic protein-1 at the protein level
in the autologous phase (Table 3), whereas also an increased
IL-13 expression was present in sdc-1 deficient mice. Finally,
we found at the protein level, in the sdc-1-deficient mice, an
increased expression of the tyrosine kinase Axl and the
chemokine epithelial cell-derived neutrophil-activating pep-
tide (ENA)-78/CXCL5, which both are involved in inflam-
matory renal diseases.31,32
In summary, sdc-1 deficiency leads to an increased
albuminuria and impaired renal function in anti-GBM
nephritis, which may be explained by a higher glomerular
PMN and macrophage influx and by higher plasma levels and
glomerular deposition of mouse Ig anti-rabbit anti-GBM
IgG. Furthermore, sdc-1 deficiency leads to an increased
antibody response against rabbit anti-GBM IgG and to a clear
shift from a Th1 to a Th2 response.
DISCUSSION
Previously, it has been shown that the HS proteoglycan sdc-1
is important for leukocyte trafficking on activated endothe-
lium.9,33 Therefore, we evaluated the role of sdc-1 in
experimental anti-GBM nephritis. The rabbit anti-GBM
serum we generated was effective in binding to the GBM
and led to glomerular C3c and fibrin deposition in the
heterologous and autologous phase of anti-GBM nephritis,
which is in accordance with previous studies15,18,20 and which
was not affected by sdc-1 deficiency. Importantly, we found
an increased glomerular sdc-1 expression 2 h after rabbit
anti-mouse GBM IgG administration in WT mice. The
increased glomerular sdc-1 expression persisted until 18 h,
whereas sdc-1 expression became normal after 4 days. We
found the same for sdc-4 expression, in this case, in both WT
and sdc-1-deficient mice. However, during anti-GBM
nephritis, the mRNA expression of sdc-1 and sdc-4 expres-
sion in WT mice was still increased after 8 days. This may be
explained by a higher turnover of the syndecans during the
heterologous phase. Furthermore, in contrast to protein
expression during anti-GBM nephritis, mRNA expression of
sdc-4 wasB2-fold higher in WT mice compared with sdc-1-
deficient mice in both the heterologous and autologous
phase. These data suggest that under inflammatory condi-
tions, sdc-1 regulates the expression of the gene encoding
sdc-4 without a clear effect on sdc-4 protein expression. The
underlying mechanisms remain unclear, but similar observa-
tions have been made for sdc-3 and sdc-4.34 Nevertheless, it
can be concluded that both sdc-1 and sdc-4 play a role during
anti-GBM nephritis and that other syndecans do not
compensate for the loss of sdc-1.
In both WT and sdc-1-deficient mice, glomerular PMN/
macrophage influx was maximal 2 h after rabbit anti-mouse
GBM IgG administration, which is consistent with previous
studies.15,18,20 However, the glomerular PMN/macrophage
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Figure 4 | Glomerular leukocyte influx in WT and sdc-1-deficient
mice during anti-GBM nephritis. (a) Glomerular PMN and
(b) macrophage influx, analyzed by immunohistochemical staining,
peaked 2 h after rabbit anti-GBM IgG administration in both WT and
sdc-1-deficient mice and at this time point was significantly higher in
sdc-1-deficient mice. After 18 h, (a, b) 4 and 8 days, the glomerular
PMN and macrophage influx was similar to untreated mice (indicated
by the dotted line) or control mice injected with rabbit IgG. (c)
Glomerular CD4þ T-cell and (d) CD8þ T-cell influx was significantly
higher in sdc-1-deficient mice after 4 and 8 days. The results are
expressed as the means7s.e.m. from eight WT and eight
sdc-1-deficient mice. ^Po0.05 versus untreated mice or mice
injected with control rabbit IgG, *Po0.01 and **Po0.001 versus
anti-GBM-injected WT mice. WT, wild type; Sdc-1/,
syndecan-1-deficient.
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influx in sdc-1-deficient mice was significantly higher com-
pared with WT mice. Furthermore, we found an enhanced
glomerular influx of CD4þ and CD8þ T cells in sdc-1-
deficient mice, in particular, during the autologous phase.
Our findings are in accordance with previous data, as an
increased adhesion of leukocytes has been shown in sdc-1-
deficient mice in a retina perfusion model and in acute lung
inflammation.9,35 It appeared that the enhanced leukocyte
adhesion mainly could be attributed to the sdc-1 deficiency
of leukocytes, which was underscored by an enhanced
adhesion of sdc-1-deficient leukocytes to activated HUVEC
in vitro.9,33 Therefore, the higher glomerular PMN influx in
sdc-1-deficient mice may be caused by an enhanced adhesion
of PMNs to the activated glomerular endothelium. This may
be explained by the impossibility of shedding, that is
proteolytic cleavage, of the ectodomain of sdc-1.36–39 This
soluble ectodomain that contains the HS side chains could
compete for proinflammatory chemokines destined for the
endothelium or could modify leukocyte adhesion by comp-
etitive binding to adhesion molecules, such as selectins and
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Figure 5 | Glomerular endothelial expression of inflammatory, N- and 6-O-sulfated, HS domains during the acute heterologous phase
of anti-GBM nephritis. (a) Immunofluorescence double staining of N- and 6-O-sulfated HS domains recognized by the anti-HS antibodies
AO4B08 (red), EW3D10 (red), EW4G2 (red), and the endothelium marker CD31 (green) showed an increased glomerular endothelial expression
of inflammatory HS domains in sdc-1-deficient mice 2 h after anti-GBM IgG administration. Original magnification  400. Semiquantitative
analysis of the glomerular endothelial expression of inflammatory HS domains recognized by (b) AO4B08, (c) EW3D10, and (d) EW4G2
colocalizing with CD31 showed a higher expression of these HS domains in sdc-1-deficient mice compared with WT mice 2 h after anti-GBM IgG
administration. The expression of CD31 was rather constant at the different time points both for the WT and the sdc-1-deficient mice. The
epitopes of the single chain anti-HS antibodies are given within parentheses. Staining intensities are expressed as means7s.e.m. from eight WT
and eight sdc-1-deficient mice in arbitrary units. Dotted lines indicate the base line score of untreated mice or mice injected with rabbit control
IgG. *Po0.001 versus anti-GBM injected WT mice. GlcNS6S, N- and 6-O-sulfated glucosamine; GlcA, glucuronic acid; IdoA2S, 2-O-sulfated
iduronic acid; WT, wild type; sdc-1/, syndelan/ deficient.
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integrins. An additional explanation for the higher PMN
influx in sdc-1-deficient mice may be the significantly higher
glomerular endothelial expression of specific inflammatory,
N- and 6-O-sulfated, HS domains in these mice compared
with WT mice at the moment of maximal PMN influx, that is
2 h after anti-GBM administration. Recently, we found that
these inflammatory HS domains are crucial for the firm
adhesion of leukocytes to activated glomerular endothelial
cells in vitro.30 At this moment, we have no mechanistic
explanation for the higher expression of these inflammatory
HS domains on activated glomerular endothelium in sdc-1-
deficient mice. We also found a higher expression of
intercellular adhesion molecule-1 in sdc-1-deficient mice
during the heterologous phase, which may indicate that the
renal endothelium in sdc-1-deficient mice is more sensitive
for inflammatory stimuli in the heterologous phase of anti-
GBM nephritis. Apparently, sdc-1 on either the glomerular
endothelium and/or on leukocytes has anti-inflammatory
properties by controlling the expression of endothelial HS
ligands for receptors on leukocytes, that is L-selectin and
Mac-1, possibly by modulating intracellular cascades.40,41
However, we can conclude that sdc-1 apparently is not the
HS proteoglycan core protein that carries HS chains with the
inflammatory, N- and 6-O-sulfated, HS domains, as these
domains are also expressed on the glomerular endothelium of
sdc-1-deficient mice.
During the acute heterologous phase that is after 18 h,
albuminuria was higher in sdc-1-deficient mice compared
with WT mice. This may be explained by the higher
glomerular PMN/macrophage influx, which could result in
more release of proteinases by these leukocytes and thus
more destruction of the capillary wall.15 This increased influx
led to a higher albuminuria at 4 h, which became significant
after 18 h. This difference in albuminuria persisted in the
autologous phase, whereas renal function of sdc-1-deficient
mice was worse after 8 days. In line with this, glomerular
injury in sdc-1-deficient mice was more severe compared
with WT mice after 4 and 8 days, which was accompanied by
an increased matrix expansion as revealed by the higher
expression of extracellular matrix components and extra-
cellular matrix remodeling enzymes. The expression of the
growth factors, transforming growth factor-b and connective
tissue growth factor, that promote glomerular scarring was
increased after 8 days, but was not different between sdc-1-
deficient and WT mice. We also identified an increased
expression of the tyrosine kinase Axl and the chemokine
neutrophil-activating peptide-78/CXCL5, which previously
have been identified in inflammatory renal diseases.31,32 As
discussed for the heterologous phase, this may be explained
by more glomerular damage mediated by PMNs and macro-
phages, initially. However, it has been reported that the
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Figure 6 | Sdc-1-deficient mice develop higher albuminuria and a
worse renal function. (a) The albumin/creatinine ratio (mg/mg)
(ACR) was significantly higher in sdc-1-deficient mice at 18 h, 4, and 8
days after anti-GBM IgG administration. The ACR of WT and
sdc-1-deficient mice at 1 h (0.4270.19 in WT mice, 0.3070.16 in
Sdc-1/ mice), 2 h (0.5470.44 in WT mice, 0.9370.56 in Sdc-1/
mice), and 4 h (1.2670.52 in WT mice, 2.0170.32 in Sdc-1/ mice)
was similar to untreated mice or mice injected with rabbit control IgG
(indicated by the dotted line). (b) Plasma creatinine concentration
(mg/dl) was significantly higher in sdc-1-deficient mice than in WT
mice at 8 days after anti-GBM IgG administration. Plasma creatinine
concentrations of WT and sdc-1-deficient mice after 1, 2, 4, 18 h, and
4 days were similar to untreated mice or mice injected with control
rabbit IgG (indicated by the dotted line). The means7s.e.m. are
shown (from eight WT and eight sdc-1-deficient mice). ^Po0.001
versus untreated mice or control mice injected with rabbit IgG,
*Po0.05 and **Po0.001 versus anti-GBM injected WT mice.
WT, wild type; Sdc-1/, syndecan-1-deficient.
WT Sdc-1–/–
Day 4
Day 8
Figure 7 | Histology of glomerular injury in WT and
sdc-1-deficient mice during anti-GBM nephritis. Glomeruli in
sdc-1-deficient mice showed more globally occluded and distended
capillaries filled with PAS-positive fibrinous material (arrows) after
4 and 8 days. In addition, proteinacious tubular casts (asterisks)
were more frequently observed in sdc-1-deficient mice compared
with WT mice. At day 8, WT mice showed thickening of capillary walls
(arrowhead) but mostly open capillary lumens. Original magnification
 250. WT, wild type; Sdc-1/, syndecan-1-deficient.
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development of mouse Ig anti-rabbit IgG and subsequent
deposition during the autologous phase may be a driving
force in persistence of albuminuria.27 Therefore, the observed
two-fold higher glomerular deposition of mouse Ig anti-
rabbit IgG in sdc-1-deficient mice may serve as an
explanation for the higher albuminuria in sdc-1-deficient
mice during the autologous phase. Notably, both WT and
sdc-1-deficient mice showed a higher response against rabbit
anti-GBM IgG compared with control rabbit IgG. This can be
explained by interference of the anti-GBM antibodies with
the immune response against rabbit anti-GBM IgG. The anti-
GBM antibodies contained reactivities against HS and agrin,
which are both present on immunological cells12,42,43 and
thus may be potential targets of the anti-GBM antibodies.
Another explanation may be that the anti-GBM rabbit IgG
serves as a planted antigen, whereas the control rabbit IgG
remains in the circulation. Furthermore, the higher response
against rabbit anti-GBM IgG in sdc-1-deficient mice may be
the result of a combination of the intrinsic sdc-1 deficiency of
certain immunological cells such as B cells44,45 and immature
dendritic cells46 and the potential effect of the anti-GBM
antibodies on these immunological cells.
The response against rabbit anti-GBM IgG is quantita-
tively and qualitatively different between WT and sdc-1-
deficient mice. First, the response against rabbit anti-GBM
IgG is higher in sdc-1-deficient mice than in WT mice.
Furthermore, sdc-1-deficient mice had higher plasma levels
of mouse IgG1 anti-rabbit IgG and lower plasma levels of
mouse IgG2a anti-rabbit IgG. This indicates a shift from a
Th1 response, identified as the major T-cell response in anti-
GBM,26 to a Th2 response in sdc-1-deficient mice. Indeed,
we found higher renal levels of Th2 (promoting) cytokines
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Figure 8 | Sdc-1-deficient mice develop higher levels of mouse Ig/IgG1 anti-rabbit IgG and lower levels of mouse IgG2a anti-rabbit
IgG than WT mice during anti-GBM nephritis. The plasma levels of total mouse Ig and IgG1 anti-rabbit IgG in the sdc-1-deficient mice
were higher, whereas plasma levels of mouse IgG2a anti-rabbit IgG were lower compared with WT mice (a) 4 and (b) 8 days after
administration of rabbit anti-GBM IgG. Glomerular mouse IgG1 deposits were higher in sdc-1-deficient mice, whereas glomerular mouse
IgG2a deposits were lower compared with WT mice (c) 4 and (d) 8 days after administration of rabbit anti-GBM IgG. The results (means7s.e.m.)
are expressed as (a, b) titers of plasma levels in U/ml or as (c, d) titers of appropriate antibodies detecting glomerular deposits in arbitrary units
from eight WT and eight sdc-1-deficient mice. *Po0.001 versus anti-GBM injected WT mice. WT, wild type; Sdc-1/, syndecan-1-deficient.
Table 3 | Semiquantitative protein expression of cytokines
and chemokines in the kidneys of wild-type and
syndecan-1-deficient mice at 8 days after rabbit anti-mouse
GBM IgG administrationa
WT Sdc-1/
IFN-g 11.2 6.60
IL-4 14.4 24.3
IL-10 o5 9.94
IL-13 8.15 13.2
MCP-1 8.86 17.6
ENA-78/CXCL5 9.81 22.6
Axl o5 10.8
ENA-78, epithelial cell-derived neutrophil activating peptide-78; IFN-g, interferon- g;
IL, interleukin; MCP-1, monocyte chemotactic protein-1; Sdc-1/, syndecan-1-
deficient mice; WT, wild-type mice.
aThe average expression of three pooled kidneys is shown and is expressed as the
integrated density. Signals lower than five (three times the signal of the negative
controls) were not evaluated. Only cytokines and chemokines that gave a difference
of more than 1.5-fold are shown.
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IL-1b, IL-4, IL-6, IL-10, IL-13, and monocyte chemotactic
protein-1 in sdc-1-deficient mice compared with WT mice in
the heterologous and/or autologous phase. Moreover, Th1
(promoting/maintaining) cytokines TNF-a, interferon-g,
IL-2, IL-12a, IL-12b, and MIP-1a were lower in the
sdc-1-deficient mice compared with the WT mice in the
heterologous and/or autologous phase. In particular,
the severe effects of sdc-1-deficiency on the expression of
monocyte chemotactic protein-1 and MIP-a during the
heterologous phase point to an early skewing from Th1 to
Th2.47 This skewing to Th2 has been described previously in
sdc-1-deficient mice with allergic lung inflammation.48
However, at this moment, it remains difficult to explain
how a shift to a Th2 response leads to aggravation of anti-GBM
nephritis, as Th2-induced antibodies in general are less effective
in complement activation than Th1-induced antibodies.
In conclusion, sdc-1 regulates the leukocyte adhesion to
activated glomerular endothelium during the heterologous
phase of anti-GBM nephritis, either directly by shedding or
indirectly via regulation of glomerular endothelial expression
of inflammatory HS domains that promote the firm adhesion
of leukocytes. Furthermore, sdc-1 influences the immune
response against rabbit anti-GBM IgG and sdc-1-deficiency
leads to a shift from Th1 to Th2 during anti-GBM nephritis.
Overall, sdc-1 seems to have anti-inflammatory properties in
anti-GBM nephritis.
MATERIALS AND METHODS
Animals
C57BL/6 mice (Jackson Laboratories, Bar Habor, ME, USA), sdc-1-
deficient mice in a C57BL/6 background,5 and New Zealand white
rabbits were bred, housed, and handled according to the guidelines
of the local animal ethics committee. Genotyping of mice with gene-
specific primers was performed as described previously.49
Isolation of mouse GBM
Glomeruli were isolated from C57/BL6 mice perfused with 0.01 M
phosphate-buffered saline (PBS) pH 7.2 with 1.25% Fe3O4.
Glomeruli were sieved through a 75-mm sieve (Endecotts, London,
UK), pelleted by a magnet, washed in PBS, resuspended in excess
distilled water, and shaken for 2 h at 41C. Subsequently, the
suspension was centrifuged for 15 min at 5910 g at 41C and the
pellet was sonicated three times for 15 s on ice with 45 s cooling
intervals. Finally, the suspension was treated with 3% Triton X-100,
2 mg/ml deoxyribonucleaseI (Roche Diagnostics GmbH, Mann-
heim, Germany) and 4% sodium deoxycholate for 18 h, washed
extensively in distilled water and lyophilized.50,51
Immunization of rabbits with mouse GBM and purification
of rabbit IgG
Rabbits were subcutaneously injected with 1 mg GBM emulsified in
complete Freund’s adjuvant (Sigma-Aldrich Chemie BV, Zwijn-
drecht, The Netherlands), followed by subcutaneous booster
injections of 1 mg GBM in incomplete Freund’s adjuvant after 3,
6, and 9 weeks. Control rabbit IgG was collected from rabbits that
were immunized with PBS in complete Freund’s adjuvant/
incomplete Freund’s adjuvant. Pooled sera were centrifuged and
passed through a 0.4-mm filter. Subsequently, IgG fractions were
purified by protein-A affinity chromatography (Amersham Bio-
sciences, Roosendaal, The Netherlands) and concentrated to 30 mg/ml
by ultrafiltration with a XM-50 Diaflow membrane (Amicon
Corporation, Danvers, MA, USA).
Characterization of rabbit anti-mouse GBM antibodies in
enzyme-linked immunosorbent assay
Purified laminin (EHS; Campro Scientific, Berlin, Germany),
agrin,52 HS (Seikagaku, Tokyo, Japan), fibronectin (Bio-Connect
BV, Huissen, The Netherlands), or collagen type IV (Sanbio BV,
Uden, The Netherlands) was coated overnight at 41C in PBS (10 mg/
well). Wells were washed with PBS/0.05% Tween 20 (PBS/Tween)
and blocked with 2% bovine serum albumin (BSA) (Sigma-Aldrich)
in PBS for 2 h and washed with PBS/Tween. Serial dilutions of rabbit
anti-mouse GBM IgG in 2% BSA/PBS were added and incubated for
1 h, wells were washed with PBS/Tween and incubated with goat
anti-rabbit Ig (Hþ L) antibody conjugated with horseradish peroxi-
dase (Jackson ImmunoReseach Laboratories Inc., West Grove, PA,
USA) in 2% BSA/PBS for 1 h. Finally, wells were washed with PBS/
Tween and incubated with tetramethylbenzidine substrate solution
(SFRI Laboratories, Berganton, France). After exactly 15 min, the
reaction was stopped with 2 M H2SO4 and absorption was measured
at 450 nm.
Induction of anti-GBM glomerulonephritis in WT and
sdc-1-deficient mice and determination of albuminuria and
creatinine
WT and sdc-1-deficient mice, 14- to 18-weeks-old, were injected in
the tail vein with 8 mg rabbit anti-mouse GBM IgG or 8 mg control
rabbit IgG. Mice were killed after 1, 2, 4 and 18 h, 4 and 8 days. Each
group comprised of eight mice. Urine was collected directly through
bladder puncture or after 18 h in metabolic cages. Collected kidneys
were fixed in 10% buffered formalin and paraffin embedded or snap
frozen in liquid nitrogen. Albumin was measured by radial
immunodiffusion (Mancini). Plasma and urinary creatinine con-
centrations were determined enzymatically (Roche Diagnostics).
RNA isolation and real-time reversed
transcription-polymerase chain reaction
Total RNA was isolated from 10 mm frozen sections of renal cortex
using the RNeasy Mini protocol including a DNase I step (Qiagen,
Venlo, The Netherlands). Reversed transcription of 1 mg RNA was
performed with Oligo dT primers and the Superscript First-Strand
Synthesis System (Invitrogen Life Technologies, Breda, The Nether-
lands). One-tenth of cDNA was used as template in real-time
polymerase chain reaction using SYBR Green Supermix (Bio-Rad,
Veenendaal, The Netherlands) with gene-specific primers (10 mM;
Isogen, Ijsselstein, The Netherlands; Table S1) on the MyiQ poly-
merase chain reaction system (Bio-Rad). Expression of the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase was used
to quantify gene expression using the DCt method.
Immunofluorescence staining
Frozen sections (2 mm) were fixed in ice-cold acetone for 10 min and
incubated with primary antibodies diluted in PBS containing 1%
BSA and 0.05% sodium azide (IF-buffer) for 45 min. Directly labeled
antibodies included goat anti-mouse C3c- and fibrinogen-fluore-
scein isothiocyanate (FITC) (Nordic, Tilburg, The Netherlands),
goat anti-rabbit IgG Alexa 488 and goat anti-mouse IgG (Hþ L),
IgG1 and IgG2a Alexa 488 (Invitrogen Life Technologies). Unlabeled
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antibodies included anti-mouse CD31 (BD Biosciences, Alphen Aan
De Rijn, The Netherlands), the vesicular stomatitis virus (VSV)-
tagged anti-HS antibodies AO4B08, EW3D10, and EW4G2 that
recognize N- and 6-O-sulfated HS domains,53–55 anti-mouse CD4
(L3T4), CD8a (Ly-2) (BD Biosciences), CD68 (MCA1957; Serotec
Ltd, Oxford, UK), and digoxigenin-labeled rabbit anti-mouse GBM.
Digoxigenin labeling was performed according to the manufacturer’s
instructions (Roche). Sections were incubated with the appropriate
IgG Alexa 488, anti-digoxigenin-FITC (Roche), or anti-VSV-Cy3
(Sigma-Aldrich) antibodies in IF-buffer for 45 min. Finally, sections
were postfixed with 1% paraformaldehyde-PBS and embedded in
VectaShield mounting medium H-1000 (Brunschwig Chemie,
Amsterdam, The Netherlands). The amount of rabbit IgG or mouse
Ig, IgG1 and IgG2a deposited along the capillary wall was quantified
by titrating the appropriate detecting antibodies. The titer was
defined as the reciprocal of the dilution, which was still positive and
expressed as arbitrary units. The staining intensities of all antibodies
were scored in 50 glomeruli on a scale between 0 and 10 (0¼ no
staining, 1¼ 10% staining intensity along the capillary wall or on
glomerular endothelial cells, with a maximum score of 10 for 100%
staining intensity). The scoring was performed by two independent
observers on blinded sections.
Renal histology
Renal sections (5 mm) were deparaffinized, rehydrated, and stained
with PAS. Sections were counterstained with hematoxylin. At least
50 glomeruli per mouse were evaluated.
Immunohistochemical staining
Glomerular sdc-1 and -4 expression and glomerular PMN influx
were determined on deparaffinized and rehydrated sections. For
syndecan detection, the sections were treated with 0.5 mg/ml
protease XXIV (Sigma-Aldrich) for 10 min at 371C, incubated with
0.02 IU/ml heparinase I and III (IBEX Technologies Inc., Montreal,
Canada) for 1 h at 371C and blocked with 10% BSA, 1.7% NaCl in
PBS for 2 h at room temperature. Sections were incubated with rat
antibodies specific for sdc-1 (CD138; clone 281-2), sdc-4 (clone KY/
8.2; BD Biosciences), or granulocytes (NIMP-R14),56 overnight at
41C or for 1 h, respectively. Subsequently, sections were incubated
with a peroxidase-labeled anti-rat antibody (Dako, Glostrup,
Denmark) in 5% normal mouse serum/PBS for 30 min followed
by incubation with 1 mg/ml diaminobenzidine (Sigma-Aldrich) in
50 mM Tris-HCl pH 7.6 with 0.001% H2O2 for 10 min. Sections were
counterstained with hematoxylin for 2 min. Two independent
observers counted PMNs on blinded sections in at least 50
glomeruli per animal.
Determination of plasma levels of mouse Ig, IgG1 and IgG2a
anti-rabbit IgG antibodies in enzyme-linked immunosorbent
assay
Rabbit Ig was coated overnight at 41C (10mg/well). Wells were
washed with PBS/Tween and blocked with 2% BSA/PBS for 2 h.
Serial dilutions of mouse plasmas were added and incubated for 1 h.
Subsequently, wells were washed with PBS/Tween, incubated with
peroxidase-conjugated goat anti-mouse Ig (Hþ L; Tebu-Bio,
Heerhugowaard, The Netherlands), goat anti-mouse IgG1, or
IgG2a antibodies (Sanbio) in 2% BSA/PBS for 1 h. The remainder
of the enzyme-linked immunosorbent assay was performed as
described above. The titer was defined as the reciprocal of the
dilution of the plasma giving an optical density of 0.5 and expressed
as U/ml.
Detection of renal cytokines/chemokines by antibody array
RayBio mouse cytokine antibody array C series 1000 (detects 96
cytokines, chemokines, and other proteins; http://www.raybiotech.
com/map/mouse_C_Series_1000.pdf) was used according to the
manufacturer’s instructions (RayBiotech, Norcross, GA, USA).
Renal extracts were prepared from three pooled half kidneys of
three separate mice by forcing the tissue through a 70 mm cell
strainer (BD Biosciences) in lysis buffer supplied by the manufac-
turer, which was supplemented with a cocktail of protease inhibitors
(Roche). Lysates were briefly sonicated on ice and centrifuged for
10 min at 15 000 g at 41C. The protein content of the supernatant
was determined by the Bicinchoninic acid assay (Sigma). Mem-
branes were incubated with 250 mg of pooled renal extract for 1 h at
room temperature. Finally, spots were developed and exposed for
different periods to Hyperfilm (GE Healthcare Europe, Diegem,
Belgium). The intensity of the spots on the films was quantified
using Image J software (http://rsb.info.nih.gov/ij).
Statistical analysis
Values are expressed as means7s.e.m. and significance was
evaluated by a one-way ANOVA and the post hoc analysis Tukey’s
multiple comparison test using GraphPad Prism, version 4.0
software (GraphPad Software Inc., San Diego, CA, USA). For
comparison between two groups, the student’s t-test was used.
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SUPPLEMENTARY MATERIAL
Table S1. Primers used in real-time polymerase chain reaction.
Figure S1. Anti-GBM staining is significantly higher in syndecan-1-
deficient mice compared with wild type mice during anti-GBM
nephritis due to expansion of GBM matrix.
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